Open

EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

To evaluate the efficacy of divarasib compared with sotorasib or adagrasib on in patient with non-small cell lung cancer

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At each visit you will get your dose of study pills. You will be asked to take the pills on a daily basis and complete a drug diary. On some visits you will have blood work drawn.

Incentives

Study Drug

In-person visits:
at least 5

Total length of participation:
until disease progression

Looking for Specific Volunteers

Able to participate:

Disease progression during or after 1-3 different treatments
You have a life expectancy of at least 12 weeks
You have an adequate organ function

Not eligible if:

You are enrolled on another trial
You are pregnant or breastfeeding
You are unable to swallow pills

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

24-1290

ClinicalTrials.gov

NCT06497556

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.